细胞免疫疗法。
Immunotherapy with cells.
机构信息
Lymphoma Program and Cell Therapy and Transplant Program, Hematology-Oncology Division, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
出版信息
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):590-597. doi: 10.1182/hematology.2020000174.
Both older and newer cell therapies have demonstrated impressive responses in otherwise poor-prognosis lymphomas. Consequently, cellular therapy now plays a major role in the management of many non-Hodgkin lymphomas. In this article, we examine the role of chimeric antigen receptor (CAR) T cells, allogeneic stem cell transplantation, and virus-directed T cells for treatment of lymphomas. We review the current indications for CAR T cells and discuss our clinical approach to selecting and treating patients with aggressive B-cell lymphomas to receive CD19-directed CAR T cells. In addition, we highlight newer cell therapies and provide an overview of promising future approaches that have the potential to transform immunotherapy with cells to treat lymphomas.
在其他预后不良的淋巴瘤中，无论是较新的还是较老的细胞疗法都显示出了令人印象深刻的疗效。因此，细胞疗法目前在许多非霍奇金淋巴瘤的治疗中发挥着重要作用。在本文中，我们研究嵌合抗原受体 (CAR) T 细胞、同种异体干细胞移植和病毒定向 T 细胞在淋巴瘤治疗中的作用。我们回顾了 CAR T 细胞的当前适应证，并讨论了我们选择和治疗接受 CD19 定向 CAR T 细胞治疗的侵袭性 B 细胞淋巴瘤患者的临床方法。此外，我们还强调了新的细胞疗法，并提供了对有潜力改变细胞免疫疗法治疗淋巴瘤的有前途的未来方法的概述。
Zotero 插件